Medicenna Therapeutics (TSE:MDNA) Trading Down 0.7% – Here’s Why

Shares of Medicenna Therapeutics Corp. (TSE:MDNA) traded down 0.7% during trading on Tuesday . The stock traded as low as C$1.42 and last traded at C$1.49. 18,287 shares changed hands during trading, a decline of 65% from the average session volume of 51,593 shares. The stock had previously closed at C$1.50.

Medicenna Therapeutics Trading Down 0.7%

The company has a market cap of C$124.28 million, a price-to-earnings ratio of -9.31 and a beta of 2.83. The company has a current ratio of 11.40, a quick ratio of 4.65 and a debt-to-equity ratio of 0.88. The firm’s 50-day moving average price is C$1.08 and its 200 day moving average price is C$1.01.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.